Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
RECURSION PHARMACEUTICALS, INC.
Last earnings +1.8% on 2026-05-06
Revenue grew 26.9% YoY; but unprofitable (net margin -863.4%).
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
RECURSION PHARMACEUTICALS, INC. shows $74.7M in FY2025 revenue (+26.9% YoY), a -863.4% net margin, and -57.0% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro$19/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001601830, latest 10-Q filed 2026-05-06) · EODHD · rules-based read · as of 6/17/2026, 11:00:46 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $10.2M | $39.8M | $44.6M | $58.8M | $74.7M |
| Gross profit | — | — | — | — | — |
| Operating income | -$183M | -$246M | -$350M | -$479M | -$648M |
| Net income | -$186M | -$239M | -$328M | -$464M | -$645M |
| Diluted EPS | -$1.49 | -$1.36 | -$1.58 | -$1.69 | -$1.44 |
| Net margin | -1832.2% | -601.0% | -736.0% | -788.0% | -863.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median
Last 90 days: 0 open-market buys · 5 sales
| 2026-06-15 | Taylor Ben R Chief Financial Officer | Tax | 5.40K @ $3.15 | $17.0K |
| 2026-06-05 | Gibson Christopher Director | Acquired (C) | 40.0K | |
| 2026-06-05 | Gibson Christopher Director | Sell | 40.0K @ $3.62 | $145K |
| 2026-06-05 | Khan Najat CEO and President | Sell | 23.6K @ $3.58 | $84.5K |
| 2026-06-03 | Bumpus Namandje Director | Sell | 4.39K @ $3.54 | $15.5K |
| 2026-06-02 | Borgeson Blake Director | Sell | 30.0K @ $3.68 | $110K |
| 2026-05-22 | Gibson Christopher Director | Acquired (C) | 40.0K | |
| 2026-05-22 | Gibson Christopher Director | Sell | 40.0K @ $3.08 | $123K |
| 2026-05-15 | Hallett David Chief Scientific Officer | Tax | 26.7K @ $3.04 | $81.0K |
| 2026-05-15 | Khan Najat CEO and President | Tax | 62.7K @ $3.04 | $191K |